- Obesity drug beloranib shows promise in Prader-Willi population in Phase 2 trials
- Six cities score grant awards for childhood obesity prevention
- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- Senate passes Drug Quality and Security Act
- FDA approves Upsher-Smith's Qudexy XR extended-release capsules
MOUNTAIN VIEW, Calif. — Vivus has reapplied to the Food and Drug Administration for approval of a drug to treat obesity, the company said Monday.
Vivus said it sent in its regulatory approval application for Qnexa (phentermine and topiramate), a drug designed to treat obese and overweight patients by inducing and maintaining weight loss.
The company originally sought approval for the drug in October 2010, though the FDA declined to approve it.